Preeclampsia Market Analysis, Size, Share & Growth Forecast 2026–2034

Low-Dose Aspirin ASPRE First-Trimester Screen-Positive High-Risk Women 62 Percent Preterm Preeclampsia Reduction at 150 mg Nightly From 11 to 14 Weeks Has Established the Screen-and-Prevent Strategy That Identifies High-Risk Women Before the Placental Maladaptation Becomes Irreversible.USPSTF and ACOG's recommendation that all women with one major or two minor preeclampsia risk factors initiate aspirin 81 mg daily between 12-28 weeks of gestation is supported by ASPRE trial data demonstrating 62% reduction in preterm preeclampsia in the high-risk population identified through combined first-trimester screening with uterine artery Doppler, placental growth factor, and mean arterial pressure. The combined screening algorithm achieves 90% sensitivity for preterm preeclampsia with 10% false positive rate compared with the traditional risk-factor-only approach that identifies only 40% of preterm cases, demonstrating that biomarker-augmented risk stratification substantially improves the cost-effectiveness of aspirin chemoprevention by concentrating benefit on those at highest risk. Implementation barriers include the limited availability of first-trimester combined screening outside academic centres and health systems with integrated biomarker infrastructure, and ACOG's advocacy for universal combined screening adoption represents the most impactful near-term change in preeclampsia prevention practice.

sFlt-1/PlGF Ratio Below 38 Providing 99.3 Percent Negative Predictive Value for Ruling Out Preeclampsia Within 1 Week Has Established the Angiogenic Factor Balance Biomarker as the Clinical Decision Tool That Avoids Unnecessary Hospitalisation for the Low-Ratio Woman.Roche's Elecsys PlGF and sFlt-1:PlGF ratio test and Thermo Fisher Scientific's BRAHMS sFlt-1/PlGF test have been incorporated into preeclampsia diagnostic algorithms in European emergency obstetric guidelines, where a sFlt-1:PlGF ratio below 38 rules out preeclampsia with 99% negative predictive value within 1 week, enabling safe outpatient management of women with suspected preeclampsia who would previously have required hospitalisation for clinical observation. The PARROT UK trial demonstrated that sFlt-1:PlGF-guided management reduced hospital admissions by 30% compared with standard assessment while maintaining equivalent maternal and neonatal safety outcomes, generating the real-world implementation evidence that supports routine biomarker testing in second and third trimester hypertensive disorder management. NHS Scotland's national implementation of the sFlt-1:PlGF pathway through the PARROT programme and its spread to NHS England and Wales provide the largest population-level evidence of biomarker-guided preeclampsia management in clinical practice.

Magnesium Sulphate MAGPIE Trial 58 Percent Eclampsia Reduction and Maternal Mortality Reduction in Severe Preeclampsia Has Established the IV Magnesium as the Universal Eclampsia Prophylaxis That Every Severe Preeclampsia Patient Receives From the NMDA Receptor Antagonism Mechanism.The StAmP trial of pravastatin in preeclampsia treatment demonstrated biomarker improvement and reduced neonatal morbidity in a small UK trial, and the STAMP and PrevPE trials are evaluating pravastatin for preeclampsia prevention in high-risk women identified by first-trimester combined screening. The statin mechanism in preeclampsia involves heme oxygenase-1 induction that produces anti-inflammatory carbon monoxide and biliverdin, upregulation of anti-angiogenic sFlt-1 clearance that reduces the placental angiogenic imbalance driving endothelial dysfunction, and endothelin-1 suppression that reduces the vasoconstriction contributing to maternal hypertension. Statins' well-established safety profile in non-pregnant patients and the availability of generic formulations at under USD 10 monthly create an attractive safety and cost profile if Phase 3 trial data confirms the Phase 2 biomarker signals of preeclampsia prevention in high-risk pregnancies identified through combined screening.

For related market intelligence, see the Postpartum Depression Market.